1. BENEFIT
Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days (n = 1,431) vs. placebo (n = 1,423).
Results
(p = 0.31)
Death, cardiac arrest, ventricular tachycardia, pacemaker or ICD implantation, cardiac transplantation, heart failure, stroke, or other thromboembolic event: 27.5% of the benznidazole group vs. 29.1% of the placebo group (p = 0.31)
Death: 17.2% vs. 18.1%, respectively for benznidazole vs. placebo
29.1 %
27.5
Conclusions
Among patients with serologic evidence of T. Cruzi and chronic cardiomyopathy, benznidazole did not prevent adverse cardiac events compared with placebo at 7 years
This lack of benefit was despite a higher rate of T. Cruzi conversion to negative status among the benznidazole group
Benznidazoletherapy
Placebo
Morillo CA, et al. N Engl J Med 2015;373: